Treats attention-deficit/hyperactivity disorder (ADHD). Sold as Strattera, Atoncy. Every FDA application for this active ingredient: 2 branded and 11 generic.
As of Nov 16, 2026, FDA lists 13 applications for Atomoxetine Hydrochloride (sold as Strattera, Atoncy), first approved Nov 26, 2002, with 4 new uses approved and 0 published complete response letters.
| Atomoxetine HCl | Part D | $33.8M | +4% | 75,248 |
| Strattera | Part D | $679K | -50% | 266 |
| Cardiovascular Safety of Atomoxetine in Children With ADHDAttention Deficit Hyperactivity Disorder · Assiut University | — | Not yet recruiting | Oct 5, 2026 |
| Study of the Effects of Atomoxetine on MotivationApathy · University of Oxford | Phase 4 | Not yet recruiting | Aug 18, 2026 |
| An Evaluation of Treatments for Sustained Clinical Response (18 Months) in Symptomatic Alzheimer's DiseaseAlzheimer's Disease (AD), Mild Cognitive Impairment Due to Alzheimer's Disease · University College, London | Phase 3 | Recruiting | Jul 23, 2026 |
| A Comparative Effectiveness Study of Positive Airway Pressure (PAP) Therapy, Dental Device, and Atomoxetine-Oxybutynin for Treatment of Obstructive Sleep Apnea in AdultsObstructive Sleep Apnea (OSA) · Sairam Parthasarathy | Phase 4 | Recruiting | Jul 1, 2026 |
| Combination Upper-Airway Electrical and Pharmacological Stimulation for Obstructive Sleep ApneaObstructive Sleep Apnea, Sleep-disordered Breathing · Brigham and Women's Hospital | Phase 1 / Phase 2 | Recruiting | May 11, 2026 |
| Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: a Multi-centre and Multi-modal ApproachParkinson's Disease (PD), Freezing of Gait · Radboud University Medical Center | Phase 3 | Recruiting | Jan 5, 2026 |
| Endotype DIrected Treatment for OSA in Down SyndromeObstructive Sleep Apnea (OSA), Down Syndrome · University of Arizona | Phase 4 | Recruiting | Dec 12, 2025 |
| Progressive Relaxation and Psychoeducation in Patients With Hematological MalignanciesHematological Cancer · Necmettin Erbakan University | Not applicable | Active, not recruiting | Nov 26, 2025 |
| Nov 26, 2002 | StratteraNDA 21411 · New molecular entity | Lilly | 36 | Discontinued |
| Sep 16, 2010 | Atomoxetine HydrochlorideANDA 79017 | Zydus Pharms USA Inc | 3 | Marketed |
| May 30, 2017 | Atomoxetine HydrochlorideANDA 78983 | Apotex | 2 | Marketed |
| May 30, 2017 | Atomoxetine HydrochlorideANDA 79016 | Aurobindo Pharma | 3 | Marketed |
| May 30, 2017 | Atomoxetine HydrochlorideANDA 79019 | Glenmark Pharms Ltd | 3 | Marketed |
| May 30, 2017 | Atomoxetine HydrochlorideANDA 79022 | Teva Pharms USA | 3 | Marketed |
| Feb 23, 2018 | Atomoxetine HydrochlorideANDA 90609 | Dr Reddys | 2 | Marketed |
| Feb 18, 2021 | Atomoxetine HydrochlorideANDA 79021 | Strides Pharma | 2 | Marketed |
| Mar 11, 2021 | Atomoxetine HydrochlorideANDA 202682 | Hetero Labs Ltd V | 1 | Marketed |
| Mar 20, 2026 | AtoncyNDA 220320 · New dosage form | Map77 | 0 | Marketed |
| Jun 16, 2026 | Atomoxetine HydrochlorideANDA 218875 | Pharmazone | 1 | Marketed |
| — | Atomoxetine HydrochlorideANDA 78940 | Actavis Elizabeth | 0 | Discontinued |
| — | Atomoxetine HydrochlorideANDA 79020 | Sun Pharma Global | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA